Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • Minnesota
  • Minneapolis


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Community-based Intervention Effects on Older Adults' Physical Activity
    NCT03326141
    Conditions:   Exercise;   Physical Activity;   Accidental Fall;   Motivation;   Older Adults
    Interventions:   Behavioral: Otago Exercise Program;   Device: Physical activity monitors (e.g., Fitbit);   Behavioral: Interpersonal Behavior Change Strategies;   Behavioral: Intrapersonal Behavior Change Strategies;   Other: Information about Health and Wellness
    Sponsors:   University of Minnesota;   National Institute of Nursing Research (NINR)
    Recruiting
  • Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
    NCT02963415
    Condition:   Preclinical Alzheimer's Disease
    Intervention:   Behavioral: Exergame
    Sponsor:   University of Minnesota
    Recruiting
  • The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI
    NCT03313895
    Condition:   Mild Cognitive Impairment
    Interventions:   Behavioral: ACT;   Behavioral: Cycling Only;   Behavioral: Cognitive Training Only;   Behavioral: Stretching and Mental Stimulating Activities
    Sponsors:   University of Minnesota;   University of Rochester;   Mayo Clinic;   University of St Thomas
    Recruiting
  • Post-contracture Release Radiation for Dupuytren's Disease
    NCT04122313
    Conditions:   Dupuytren's Disease;   Dupuytren Contracture;   Dupuytren Disease of Palm and Finger;   Dupuytren Disease of Finger;   Dupuytrens Contracture of Both Hands;   Dupuytren's Disease of Palm of Right Hand;   Dupuytren's Disease of Palm of Left Hand;   Dupuytren Contracture of Right Palm;   Dupuytren Contracture of Left Palm;   Dupuytren's Contracture Left;   Dupuytren's Contracture Right
    Intervention:   Other: Evaluation of Dupuytren's Disease Treatment
    Sponsor:   University of Minnesota
    Recruiting
  • Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)
    NCT04040387
    Conditions:   Stress Disorders, Post-Traumatic;   Combat Disorders;   Ptsd;   Nightmare;   Nightmares, REM-Sleep Type;   Nightmare Disorder With Associated Non-Sleep Disorder
    Interventions:   Device: NightWare Therapeutic System;   Device: Sham NightWare
    Sponsors:   NightWare;   Minneapolis Veterans Affairs Medical Center
    Recruiting
  • Problem-Solving Therapy for Depressive Symptoms and Quality of Life in Stroke Survivor-Caregiver Dyads
    NCT04035681
    Conditions:   Stroke;   Quality of Life;   Depression
    Interventions:   Behavioral: Problem-Solving Therapy;   Other: Stroke-Related Health Education
    Sponsors:   Allina Health System;   University of Minnesota
    Recruiting
  • Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
    NCT04032301
    Conditions:   Post-Traumatic Stress Disorders;   Major Depressive Disorder
    Interventions:   Drug: Ketamine;   Other: Normal Saline
    Sponsors:   University of Minnesota;   Minneapolis Veterans Affairs Medical Center
    Recruiting
  • IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
    NCT04028960
    Condition:   Type1diabetes
    Interventions:   Drug: Regular insulin (Humulin-R), intranasal route;   Device: SipNose intranasal device
    Sponsors:   HealthPartners Institute;   International Diabetes Center at Park Nicollet;   Juvenile Diabetes Research Foundation
    Recruiting
  • FT516 in Subjects With Advanced Hematologic Malignancies
    NCT04023071
    Conditions:   Acute Myelogenous Leukemia;   B-cell Lymphoma
    Interventions:   Drug: FT516;   Drug: Rituximab;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: IL-2
    Sponsor:   Fate Therapeutics
    Recruiting
  • Cf-DNA Assay During Treatment of Acute Rejection
    NCT04019353
    Conditions:   Kidney Transplant Failure and Rejection;   Kidney Transplant; Complications;   Kidney Transplant Rejection;   Transplant; Complication, Rejection;   Transplant Dysfunction
    Intervention:   Genetic: cf-DNA Collection
    Sponsor:   University of Minnesota
    Recruiting
  • Allogeneic Skin Grafting
    NCT04015947
    Condition:   GVHD
    Intervention:   Device: CelluTome® Epidermal Harvesting System
    Sponsor:   University of Minnesota
    Recruiting
  • State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
    NCT04011449
    Conditions:   Parkinson Disease;   Parkinson
    Intervention:   Device: Medtronic RC+S DBS system
    Sponsor:   University of Minnesota
    Recruiting
  • Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa
    NCT04007900
    Conditions:   Anorexia Nervosa;   Anorexia
    Intervention:   Behavioral: Positive Affect Treatment
    Sponsor:   University of Minnesota
    Recruiting
  • Hepatic Energy Fluxes in NASH and NAS Patients
    NCT03997422
    Conditions:   NASH - Nonalcoholic Steatohepatitis;   NAS;   Overweight or Obesity;   Weight Loss;   Bariatric Surgery Candidate
    Intervention:   Procedure: Vertical Sleeve Gastrectomy (VSG)
    Sponsor:   University of Minnesota
    Recruiting
  • Algorithms for Programming DBS Systems for ET
    NCT03984643
    Condition:   Essential Tremor
    Intervention:   Device: Vim-Deep Brain Stimulation
    Sponsor:   University of Minnesota
    Recruiting
  • Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
    NCT03981705
    Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer
    Intervention:   Radiation: Standard Trimodality Breast Imaging
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Low Sulfur Fecal Transplant for Ulcerative Colitis
    NCT03948919
    Condition:   Ulcerative Colitis
    Interventions:   Drug: Fecal microbiota;   Other: Placebo
    Sponsor:   University of Minnesota
    Recruiting
  • Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
    NCT03942653
    Condition:   Salivary Gland Carcinoma
    Interventions:   Drug: Goserelin Acetate;   Drug: Pembrolizumab
    Sponsors:   Big Ten Cancer Research Consortium;   Merck Sharp & Dohme Corp.;   TerSera Therapeutics
    Recruiting
  • Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer
    NCT03934840
    Condition:   Prostate Cancer
    Interventions:   Drug: Cabazitaxel;   Drug: Carboplatin;   Drug: Abiraterone;   Drug: Prednisone
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Training for Health Professionals In Tanzania
    NCT03923582
    Conditions:   Health Knowledge, Attitudes, Practice;   Training
    Intervention:   Behavioral: Health Curriculum Training
    Sponsors:   University of Minnesota;   Muhimbili University of Health and Allied Sciences;   Johns Hopkins University
    Recruiting
  • The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
    NCT03921658
    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Intervention:  
    Sponsors:   University of Minnesota;   United States Department of Defense
    Recruiting
  • Care to Plan: a Tailored Resource for Family Members of Persons With Dementia
    NCT03901456
    Conditions:   Dementia;   Alzheimer Disease;   Memory Loss
    Interventions:   Behavioral: Care to Plan;   Behavioral: Usual Care
    Sponsors:   University of Minnesota;   National Institute on Aging (NIA)
    Recruiting
  • Adoptive Transfer of Haploidentical NK Cells and N-803
    NCT03899480
    Conditions:   Hiv;   HIV Infections;   Immune Deficiency
    Intervention:   Biological: Haploidentical Natural Killer (NK) Cells
    Sponsor:   University of Minnesota
    Recruiting
  • Immunologic Effects of Radioembolization of Primary and Secondary Liver Malignancies
    NCT03889093
    Conditions:   Hepatocellular Carcinoma;   Secondary Malignant Neoplasm of Liver
    Intervention:   Other: Yttrium-90
    Sponsor:   University of Minnesota
    Recruiting
  • Advanced Reperfusion Strategies for Refractory Cardiac Arrest
    NCT03880565
    Conditions:   Cardiac Arrest;   Extracorporeal Membrane Oxygenation Complication;   Ventricular Fibrillation;   Pulseless Ventricular Tachycardia;   Out-Of-Hospital Cardiac Arrest
    Interventions:   Device: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation;   Device: Standard Advanced Cardiac Life Support (ACLS) Resuscitation
    Sponsor:   University of Minnesota
    Recruiting
  • Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
    NCT03852992
    Conditions:   Male Pattern Hair Loss;   Androgenetic Alopecia;   Male Pattern Baldness
    Interventions:   Drug: Post-Laser Minoxidil 2%;   Drug: At-Home Minoxidil 5%;   Device: Laser;   Drug: Post-laser 5mg minoxidil;   Drug: Post-laser 10mg minoxidil;   Drug: Post-laser 20mg minoxidil
    Sponsor:   University of Minnesota
    Recruiting
  • Cystic Fibrosis and Cognitive Function
    NCT03820349
    Condition:   Cystic Fibrosis
    Intervention:  
    Sponsor:   University of Minnesota
    Recruiting
  • Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis
    NCT03779139
    Conditions:   Chronic Pancreatitis;   Diabetes Mellitus;   Islet Cell Transplantation
    Interventions:   Procedure: Intrahepatic islets and islets in the omental pouch;   Procedure: Intrahepatic islets alone;   Other: Normal Volunteers
    Sponsor:   University of Minnesota
    Recruiting
  • Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg
    NCT03762915
    Conditions:   SRP;   Minocycline HCl Microspheres;   Biomarkers
    Intervention:   Drug: minocycline HCl microspheres
    Sponsors:   University of Minnesota;   Bausch Health Companies, INC.
    Recruiting
  • Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures
    NCT03744728
    Condition:   Bloodstream Infection
    Interventions:   Diagnostic Test: Accelerate PhenoTest™ BC kit;   Diagnostic Test: Standard of Care
    Sponsor:   Accelerate Diagnostics, Inc.
    Recruiting
  • Trial of Indole-3-Carbinol and Silibinin
    NCT03687073
    Condition:   Smoking
    Interventions:   Drug: Indole-3-Carbinol;   Drug: Silibinin;   Drug: Silibin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • A Study of FMT in Patients With AML Allo HSCT in Recipients
    NCT03678493
    Conditions:   Acute Myeloid Leukemia;   Allogeneic Hematopoietic Cell Transplantation
    Interventions:   Biological: Fecal Microbiota Transplant (FMT);   Other: Placebo
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Spectroscopic Magnetic Resonance Imaging of Glioma
    NCT03677999
    Condition:   Brain Tumor-Glioma
    Intervention:   Diagnostic Test: MEGA-PRESS sequence Magnetic Resonance Spectroscopy
    Sponsor:   University of Minnesota
    Recruiting
  • Neuromodulation Augmented Cognitive Training to Improve Cognitive Flexibility in Anorexia Nervosa
    NCT03647943
    Conditions:   Active tDCS;   Sham tDCS
    Interventions:   Device: Transcranial direct current stimulation;   Device: Sham transcranial direct current stimulation
    Sponsor:   University of Minnesota
    Recruiting
  • mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management
    NCT03612271
    Condition:   Hypertension
    Intervention:   Behavioral: mGlide
    Sponsors:   University of Minnesota;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training
    NCT03609203
    Condition:   Allogeneic HCT Survivors
    Interventions:   Other: 10 Weeks of Strength Trailing;   Other: Group Nutrition Discussion: week 1, week 5 and week 10
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Liposome Bupivacaine in Interscalene Block for Rotator Cuff Repair
    NCT03587584
    Condition:   Acute Pain
    Interventions:   Drug: liposomal bupivacaine;   Drug: Bupivacaine
    Sponsor:   University of Minnesota
    Recruiting
  • Effect of Constraint-Induced Gaming Therapy in an Acute Care Setting
    NCT03578536
    Condition:   Stroke
    Intervention:   Device: Recovery Rapids
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Splenic Embolization for Portal Hypertension
    NCT03532750
    Condition:   Portal Hypertension
    Interventions:   Device: Particle;   Device: Coil
    Sponsor:   University of Minnesota
    Recruiting
  • Role of CGMS Usage in Predicting Risk for Hypoglycemia
    NCT03481530
    Conditions:   Type 2 Diabetes Mellitus;   Hypoglycemia
    Intervention:   Device: Continuing Glucose Monitor System
    Sponsor:   University of Minnesota
    Recruiting
  • The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa
    NCT03414112
    Condition:   Anorexia Nervosa
    Intervention:   Biological: Intranasal oxytocin
    Sponsors:   University of Minnesota;   Klarman Foundation
    Recruiting
  • Post Acute Cardiac Event Smoking (PACES) Study
    NCT03413423
    Conditions:   Acute Coronary Syndrome;   Tobacco Use
    Interventions:   Behavioral: BAT-CS;   Behavioral: Smoking Cessation and Health & Wellness
    Sponsors:   Hennepin Healthcare Research Institute.;   Minneapolis Heart Institute Foundation;   The Miriam Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   University of Minnesota
    Recruiting
  • Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)
    NCT03410277
    Condition:   Diabetes Mellitus, Type 1
    Intervention:   Other: Experimental hypoglycemia
    Sponsor:   University of Minnesota
    Recruiting
  • Post C-Section Pain Control Using EXPAREL
    NCT03377595
    Condition:   Pain, Postoperative
    Intervention:   Drug: Exparel
    Sponsor:   University of Minnesota
    Recruiting
  • Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
    NCT03346668
    Conditions:   Scarring Alopecia;   Frontal Fibrosing Alopecia;   Lichen Planopilaris;   Central Centrifugal Cicatricial Alopecia;   Central Centrifugal Scarring Alopecia
    Intervention:   Drug: Topical gabapentin
    Sponsor:   University of Minnesota
    Recruiting
  • Cortical Spreading Depolarization After Severe Traumatic Brain Injury
    NCT03321370
    Condition:   Traumatic Brain Injury
    Intervention:   Diagnostic Test: Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention
    Sponsor:   Hennepin County Medical Center, Minneapolis
    Recruiting
  • Assessment of Markers of Stress in Acute Ischemic Stroke With Hyperglycemia
    NCT03318679
    Conditions:   Ischemic Stroke;   Hyperglycemia
    Intervention:   Other: No intervention is planned.
    Sponsor:   University of Minnesota
    Recruiting
  • Assessing Leg Control in People With Chronic Stroke
    NCT03271463
    Condition:   Chronic Stroke
    Intervention:   Behavioral: Selective Control Assessment of Lower Extremity (SCALE)
    Sponsor:   University of Minnesota
    Recruiting
  • Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
    NCT03259581
    Conditions:   Hepatocellular Carcinoma;   Bilirubinemia
    Intervention:   Combination Product: Transarterial chemoembolization
    Sponsor:   University of Minnesota
    Recruiting
  • Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract
    NCT03218085
    Conditions:   HIV/AIDS;   Menopause;   Inflammation Vagina
    Interventions:   Drug: Tenofovir;   Drug: Emtricitabine
    Sponsors:   University of Minnesota;   American College of Clinical Pharmacy
    Recruiting
  • GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE™) for High Risk Heme Malignancies
    NCT03214666
    Conditions:   High-risk Myelodysplastic Syndromes;   Acute Myelogenous Leukemia;   Systemic Mastocytosis;   Mast Cell Leukemia
    Interventions:   Drug: GTB-3550 TriKE™ Phase I;   Drug: GTB-3550 TriKE™ Phase II
    Sponsor:   GT Biopharma, Inc.
    Recruiting
  • Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
    NCT03213964
    Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: FATE-NK100;   Drug: Interleukin-2
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy
    NCT03195868
    Conditions:   Neuropathy;   Neuropathy, Diabetic;   Neuropathy Toxic
    Intervention:   Device: Realief Therapy
    Sponsor:   University of Minnesota
    Recruiting
  • Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients
    NCT03170414
    Conditions:   HIV;   Awaiting Organ Transplant
    Intervention:  
    Sponsor:   University of Minnesota
    Recruiting
  • Naloxone, Hypoglycemia and Exercise
    NCT03149770
    Condition:   Diabetes Mellitus, Type 1
    Interventions:   Drug: Naloxone;   Drug: Placebo
    Sponsor:   University of Minnesota
    Recruiting
  • Leg Exercise During ECMO
    NCT03135210
    Condition:   Refractory Respiratory Failure
    Interventions:   Other: Open-Chain Leg Exercise;   Device: Closed-Chain Leg Exercise
    Sponsor:   University of Minnesota
    Recruiting
  • Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3
    NCT03079037
    Condition:   Parkinson Disease
    Intervention:   Device: Stimulation
    Sponsor:   University of Minnesota
    Recruiting
  • Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes
    NCT03056872
    Conditions:   Alcohol Use Disorder;   Anxiety Disorder/Anxiety State;   Stress Disorder;   Hypothalamic Pituitary Adrenal;   Drinking to Cope
    Intervention:  
    Sponsors:   University of Minnesota;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
    NCT03054909
    Conditions:   FIGO Stage III and IV Ovarian Cancer;   FIGO Stage III and IV Fallopian Tube Cancer;   FIGO Stage III Primary Peritoneal Cancer
    Interventions:   Biological: ALT-803 Subcutaneous;   Biological: ALT-803 Intraperitoneal
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
    NCT03005379
    Condition:   Clostridium Difficile Infection
    Interventions:   Drug: Fecal Microbiota Therapy (FMT);   Drug: Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
    NCT02989844
    Conditions:   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS)
    Intervention:   Drug: N-803
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Assessment of Brain Activities in Cervical Dystonia
    NCT02959645
    Condition:   Cervical Dystonia
    Intervention:  
    Sponsor:   University of Minnesota
    Recruiting
  • Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures
    NCT02957240
    Conditions:   Musculoskeletal Pain;   Fractures, Closed;   Distal Radius Fracture;   Complex Regional Pain Syndromes
    Interventions:   Behavioral: Standard Care;   Behavioral: Motor Representation Techniques
    Sponsors:   University of Minnesota;   American Hand Therapy Foundation;   Fairview Health Services
    Recruiting
  • Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
    NCT02930889
    Condition:   Benign Prostatic Hyperplasia
    Intervention:   Device: Prostate Artery Embolization
    Sponsor:   University of Minnesota
    Recruiting
  • The Residential Care Transition Module
    NCT02915939
    Conditions:   Alzheimer Disease;   Dementia
    Intervention:   Behavioral: The Residential Care Transition Module
    Sponsors:   University of Minnesota;   Johns Hopkins University;   NYU Langone Health;   Benjamin Rose Institute;   Emory University
    Recruiting
  • Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA
    NCT02829593
    Conditions:   Type 1 Diabetes;   Healthy
    Intervention:   Other: hypoglycemia (low blood sugar) and MRI
    Sponsor:   University of Minnesota
    Recruiting
  • Anti-inflammatory Therapy to Improve Outcomes After TPIAT
    NCT02713997
    Condition:   Pancreatitis, Chronic; Diabetes; Transplant
    Interventions:   Drug: etanercept;   Drug: Alpha 1-Antitrypsin
    Sponsors:   University of Minnesota;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
    NCT02636283
    Condition:   Peripheral Arterial Disease
    Interventions:   Drug: Entresto;   Drug: Placebo group
    Sponsors:   University of Minnesota;   American Heart Association
    Recruiting
  • Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI
    NCT02550366
    Condition:   Cardiac Disease
    Intervention:   Drug: MRI Contrast
    Sponsor:   University of Minnesota
    Recruiting
  • Beta-blockers in Pulmonary Arterial Hypertension
    NCT02507011
    Condition:   Pulmonary Arterial Hypertension
    Interventions:   Drug: Carvedilol;   Drug: Placebo
    Sponsor:   University of Minnesota
    Recruiting
  • Predicting Rupture of AAA by Anatomic and Hemodynamic Markers
    NCT02463760
    Condition:   Aortic Aneurysm, Abdominal
    Intervention:   Other: Medical imaging
    Sponsor:   University of Minnesota
    Recruiting
  • The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease
    NCT02252588
    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Chlorhexidine;   Other: Placebo
    Sponsors:   University of Minnesota;   Veterans Medical Research Foundation;   Flight Attendant Medical Research Institute
    Recruiting
  • Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens
    NCT02128711
    Condition:   Cystic Fibrosis
    Intervention:  
    Sponsors:   University of Minnesota;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Spinal Cord Stimulation to Treat Hypertension
    NCT02828436
    Condition:   Hypertension
    Interventions:   Device: Precision Spectra System;   Behavioral: Exercise Intervention
    Sponsor:   University of Minnesota
    Recruiting
  • Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients
    NCT04083690
    Condition:   Heart Failure, Systolic
    Intervention:   Device: Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
    Sponsor:   Allina Health System
    Recruiting
  • Safety and Efficacy Study of the SoundBite™ Crossing System With ACTIVE Wire in Coronary CTOs.
    NCT03521804
    Condition:   Chronic Total Occlusion of Coronary Artery
    Intervention:   Device: SoundBite™ Crossing System Active Wire 14
    Sponsors:   SoundBite Medical Solutions, Inc.;   ethica Clinical Research Inc.;   Cardiovascular Research Foundation, New York
    Recruiting
  • Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
    NCT02583672
    Condition:   Gaucher Disease Type 1
    Intervention:   Drug: N-acetylcysteine
    Sponsors:   University of Minnesota;   Rare Diseases Clinical Research Network;   National Center for Advancing Translational Science (NCATS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Neurological Disorders and Stroke (NINDS);   Lysosomal Disease Network
    Recruiting
  • Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes
    NCT03944616
    Condition:   Type 2 Diabetes
    Interventions:   Behavioral: Diet Beverage;   Behavioral: Water
    Sponsors:   University of California, Irvine;   University of Minnesota;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Pioglitazone for the Treatment of Alcohol Use Disorder
    NCT03864146
    Condition:   Alcohol Use Disorder
    Intervention:   Behavioral: Brief Behavioral Compliance Enhancement Treatment
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Seven vs. 14 Days Treatment for Male Urinary Tract Infection
    NCT01994538
    Condition:   Urinary Tract Infections
    Interventions:   Other: Longer therapy duration;   Other: Shorter therapy duration
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Dysphonia, Distress, and Perceived Control: Technology Based Assessment and Intervention
    NCT03576365
    Conditions:   Functional Dysphonia;   Voice Disorders;   Dysphonia
    Interventions:   Behavioral: VOICE Intervention Arm;   Behavioral: Information-Only Arm
    Sponsors:   University of Minnesota;   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting
  • Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS
    NCT03202017
    Condition:   Amyotrophic Lateral Sclerosis
    Interventions:   Procedure: Expiratory Muscle Strength Training (EMST);   Procedure: EMST + Lung Volume Recruitment (LVR)
    Sponsor:   University of Minnesota
    Recruiting
  • Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
    NCT01562626
    Conditions:   Tumors;   Neoplasms;   Cancer
    Interventions:   Drug: APS001F;   Drug: Flucytosine (5-FC);   Drug: 10% maltose
    Sponsor:   Anaeropharma Science, Inc.
    Recruiting
  • Improving Outcome for Family Caregivers of Older Adults With Complex Conditions: The Adult Day Plus (ADS Plus) Program
    NCT02927821
    Condition:   Stress
    Intervention:   Behavioral: ADS Plus
    Sponsors:   Johns Hopkins University;   University of Minnesota;   National Institute on Aging (NIA)
    Recruiting
  • Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
    NCT02356159
    Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
    NCT02002819
    Condition:   Alzheimer's Disease
    Intervention:   Drug: levetiracetam
    Sponsor:   University of Minnesota
    Recruiting
  • EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture
    NCT03955458
    Conditions:   Hip Fractures;   Intertrochanteric Fractures
    Interventions:   Drug: EXPAREL;   Drug: Ropivacaine;   Drug: Bupivacaine Hydrochloride
    Sponsor:   Pacira Pharmaceuticals, Inc
    Recruiting
  • Non-Invasive and Non-Contact Intracranial Pressure Waveform Recording Using Dynamic Video Ophthalmoscopy
    NCT04046523
    Condition:   Intracranial Pressure Increase
    Intervention:   Device: Video ophthalmoscope
    Sponsor:   University of Minnesota
    Recruiting
  • Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
    NCT03557749
    Conditions:   Immune and Microbial Reconstitution;   Systemic Viral Infection;   Acute-graft-versus-host Disease;   Chronic Graft-versus-host-disease;   Recurrent Malignancy;   Cytokine Release Syndrome;   Allogenic Related Donors;   Cell Therapy/Immunotherapy Patients
    Interventions:   Diagnostic Test: Blood Sample;   Diagnostic Test: Stool Sample;   Diagnostic Test: Urine Sample;   Diagnostic Test: Bronchoalveolar Lavage (BAL) fluid;   Diagnostic Test: Gastrointestinal biopsy x 2-4;   Diagnostic Test: Skin biopsy;   Diagnostic Test: Skin, mouth, and/or ocular swab;   Diagnostic Test: Apheresis Product;   Diagnostic Test: Final cellular product
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • International PPB/DICER1 Registry
    NCT03382158
    Conditions:   Pleuropulmonary Blastoma;   Sertoli-Leydig Cell Tumor;   DICER1 Syndrome;   Cystic Nephroma;   Wilms Tumor;   Pineoblastoma;   Renal Sarcoma;   Nodular Hyperplasia of Thyroid;   Nasal Chondromesenchymal Hamartoma;   Ciliary Body Medulloepithelioma;   Neuroblastoma;   Pituitary Cancer;   Embryonal Rhabdomyosarcoma
    Intervention:  
    Sponsors:   Children's Hospitals and Clinics of Minnesota;   Children's Research Institute;   Washington University School of Medicine;   ResourcePath, LLC;   Beijing Children's Hospital;   University of Cambridge;   Emory University;   Dana-Farber Cancer Institute
    Recruiting
  • Auto Stem Cell Transplant for Lymphoma Patients
    NCT03125642
    Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic
    NCT02988466
    Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME
    NCT02973815
    Conditions:   Obesity, Childhood;   Physical Activity;   Food Intake;   Rural Health
    Intervention:   Behavioral: NU-HOME Intervention
    Sponsors:   University of Minnesota;   Allina Health System;   Minneapolis Heart Institute Foundation
    Recruiting
  • Clinical Performance of a New Esthetic, Self-ligating Orthodontic Bracket
    NCT02959671
    Condition:   Malocclusion
    Intervention:   Device: Lower Anterior EXD-952 Self-ligating Brackets
    Sponsors:   University of Minnesota;   3M Oral Care
    Recruiting
  • UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
    NCT02722668
    Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Exemestane in Post-Menopausal Women With NSCLC
    NCT02666105
    Condition:   Non-Small Cell Lung Cancer
    Intervention:   Drug: Exemestane
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Allo HSCT Using RIC for Hematological Diseases
    NCT02661035
    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
    NCT02525029
    Condition:   Graft vs Host Disease
    Intervention:   Drug: Pregnyl®
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Gulf War Illness Inflammation Reduction Trial
    NCT02506192
    Conditions:   Chronic Inflammation;   Chronic Pain;   Fatigue;   Cognitive Impairment
    Interventions:   Drug: Delayed-Release Prednisone;   Drug: Placebo
    Sponsors:   Minneapolis Veterans Affairs Medical Center;   United States Department of Defense
    Recruiting
  • Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
    NCT02162420
    Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
    NCT02161783
    Conditions:   Primary Graft Failure;   Secondary Graft Failure
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Hematopoietic stem cell infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
    NCT01166009
    Conditions:   Autologous Stem Cell Transplantation;   Allogeneic Stem Cell Transplantation;   Solid Tumors;   Blood Cancers
    Intervention:  
    Sponsor:   Center for International Blood and Marrow Transplant Research
    Recruiting
  • Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
    NCT00630565
    Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: bone marrow transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • Alport Syndrome Treatments and Outcomes Registry
    NCT00481130
    Condition:   Alport Syndrome
    Intervention:  
    Sponsor:   University of Minnesota
    Recruiting
  • Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
    NCT00432094
    Conditions:   Childhood Germ Cell Tumor;   Ovarian Cancer;   Teratoma
    Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide;   Drug: paclitaxel;   Drug: thiotepa;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: Mesna;   Biological: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting
  • A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations
    NCT03651830
    Condition:   Amputation
    Interventions:   Device: Prosthetic Foot Emulator;   Device: Commercially available prosthetic feet
    Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System;   Minneapolis Veterans Affairs Medical Center;   Brooke Army Medical Center;   Stanford University;   University of Washington
    Recruiting
  • Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain
    NCT03581123
    Conditions:   Acute Pain;   Low Back Pain, Mechanical
    Interventions:   Behavioral: Supported-Self Management (SSM);   Other: Spinal Manipulation Therapy (SMT);   Combination Product: SMT + SSM;   Drug: Standard Medical Care (SMC)
    Sponsors:   University of Minnesota;   University of Pittsburgh;   University of Washington;   University of North Texas Health Science Center;   Oregon Health and Science University;   Duke University
    Recruiting
  • Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
    NCT04106167
    Conditions:   Advanced Solid Tumor;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small-cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Intervention:   Genetic: Allogeneic natural killer (NK) cell
    Sponsor:   Fate Therapeutics
    Recruiting
  • UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
    NCT04075656
    Condition:   Idiopathic Nephrotic Syndrome
    Interventions:   Behavioral: Standard of Care;   Behavioral: UrApp
    Sponsors:   Emory University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
    NCT03841110
    Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
    Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Fate Therapeutics
    Recruiting
  • Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
    NCT03732950
    Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Intervention:   Biological: Pembrolizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma
    NCT03554083
    Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8
    Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Drug: Vemurafenib
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Genentech, Inc.;   Stand Up To Cancer
    Recruiting
  • CAP-Ketamine for Antidepressant Resistant PTSD
    NCT02655692
    Conditions:   PTSD;   Posttraumatic Stress Disorder
    Interventions:   Drug: Ketamine;   Drug: Placebo
    Sponsors:   VA Office of Research and Development;   The University of Texas Health Science Center at San Antonio;   Brooke Army Medical Center;   Minneapolis Veterans Affairs Medical Center
    Recruiting
  • Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
    NCT03663933
    Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
    Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Improving Veteran Adherence to Treatment for PTSD Through Partnering With Families
    NCT03256227
    Condition:   Posttraumatic Stress Disorder
    Interventions:   Behavioral: Family Supported Prolonged Exposure;   Behavioral: Standard Prolonged Exposure
    Sponsor:   VA Office of Research and Development
    Recruiting
  • D2D Normative Data for Remote Assessments
    NCT03206775
    Condition:   Cognition
    Interventions:   Behavioral: Cognitive Assessments (Phase 1);   Behavioral: Cognitive Battery A (Phase 2);   Behavioral: Cognitive Battery B (Phase 2);   Behavioral: Cognitive Battery C (Phase 2)
    Sponsors:   University of Minnesota;   University of California, San Francisco;   Posit Science Corporation
    Recruiting
  • A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD
    NCT03604692
    Condition:   Chronic Graft-versus-host-disease
    Intervention:   Drug: SNDX-6352
    Sponsor:   Syndax Pharmaceuticals
    Recruiting
  • A Study of CNSA-001 in Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia
    NCT03519711
    Conditions:   BH4 Deficiency;   Hyperphenylalaninemia, Non-Phenylketonuric
    Intervention:   Drug: CNSA-001
    Sponsor:   Censa Pharmaceuticals, Inc.
    Recruiting
  • NAN-101 in Patients With Class III Heart Failure
    NCT04179643
    Conditions:   Congestive Heart Failure;   Heart Failure;   Heart Disease, Ischemic;   Cardiovascular Diseases;   Heart Failure, Systolic;   Heart Failure,Congestive;   Heart Arrhythmia;   Heart Failure, Diastolic;   Heart; Complications
    Intervention:   Biological: 3 x 10e13vg NAN-101
    Sponsor:   Asklepios Biopharmaceutical, Inc.
    Recruiting
  • walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis
    NCT03538756
    Conditions:   Sensory Peripheral Neuropathy;   Balance; Distorted;   Sensation Disorders
    Intervention:   Device: Walkasins
    Sponsor:   RxFunction Inc.
    Recruiting
  • FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
    NCT03319459
    Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreatic Cancer;   Melanoma
    Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
    Sponsor:   Fate Therapeutics
    Recruiting
  • Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
    NCT03300557
    Conditions:   Atypical Hyperplasia;   Endometrial Intraepithelial Neoplasia;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
    Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney
    NCT02210650
    Condition:   Ureteral Stones
    Interventions:   Procedure: Ureteral stone removal;   Procedure: Asymptomatic kidney stones and ureteral stone removed
    Sponsors:   Indiana Kidney Stone Institute;   University of Washington Medical Center Department of Urology (Seattle, WA);   VA Puget Sound Health Care System
    Recruiting
  • Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
    NCT03016741
    Conditions:   Castration-Resistant Prostatic Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer;   Hormone-Refractory Prostate Cancer
    Interventions:   Biological: GnRH agonist/antagonist;   Drug: Prednisone;   Drug: Abiraterone Acetate;   Drug: Enzalutamide
    Sponsor:   Northwestern University
    Recruiting
  • Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
    NCT02876640
    Conditions:   Early-Stage Breast Carcinoma;   Invasive Breast Carcinoma
    Interventions:   Drug: Retinoid 9cUAB30;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • CoQ10 in Gulf War Illness
    NCT02865460
    Conditions:   Gulf War Illness;   Chronic Fatigue;   Ubiquinol;   Coenzyme Q10
    Interventions:   Drug: Ubiquinol;   Drug: Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
    NCT03502746
    Condition:   Mesothelioma, Malignant
    Interventions:   Drug: Nivolumab;   Drug: Ramucirumab
    Sponsors:   Arkadiusz Z. Dudek, MD;   HealthPartners Institute Regions Cancer Care Center;   Eli Lilly and Company;   Bristol-Myers Squibb
    Recruiting
  • Genetic Modifiers of Cystic Fibrosis Related Diabetes
    NCT01113216
    Condition:   Cystic Fibrosis Related Diabetes
    Intervention:  
    Sponsors:   Johns Hopkins University;   Cystic Fibrosis Foundation;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Minnesota;   Northwestern University
    Recruiting
  • Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure
    NCT03056157
    Conditions:   Post-traumatic Stress Disorder;   Moral Injury;   Traumatic Loss
    Interventions:   Behavioral: Adaptive Disclosure for Moral Injury and Loss;   Behavioral: Present Centered Therapy
    Sponsors:   VA Office of Research and Development;   Minneapolis Veterans Affairs Medical Center;   San Francisco Veterans Affairs Medical Center;   San Diego Veterans Healthcare System
    Recruiting
  • Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
    NCT02867384
    Condition:   Graft vs. Host Disease
    Interventions:   Drug: Obinutuzumab;   Drug: Placebo
    Sponsors:   Dana-Farber Cancer Institute;   Roche-Genentech
    Recruiting
  • Mindful Movement for Physical Activity and Wellbeing in Older Adults- A Hybrid Effectiveness-Implementation Study
    NCT03929393
    Conditions:   Physical Inactivty;   Wellbeing;   Mindfulness
    Interventions:   Behavioral: Mindful Movement;   Other: Keys to Health & Wellbeing
    Sponsors:   University of Minnesota;   YMCA;   National Center for Complementary and Integrative Health (NCCIH)
    Recruiting
  • Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
    NCT03737981
    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
    NCT03633331
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Dried Blood Spot Testing of CMV Detection in HCT Recipients
    NCT03910478
    Condition:   Cytomegalovirus Infection
    Interventions:   Device: DBS Self-Collection Kit;   Other: Standard Control Strategy
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis
    NCT03042104
    Conditions:   Aortic Stenosis;   Heart Diseases
    Intervention:   Device: Edwards SAPIEN 3 THV
    Sponsor:   Edwards Lifesciences
    Recruiting
  • Diuretic Comparison Project
    NCT02185417
    Condition:   Hypertension
    Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Mepo for EoE Study
    NCT03656380
    Conditions:   EoE;   Eosinophilic Esophagitis
    Interventions:   Drug: Mepolizumab 300 mg;   Drug: Mepolizumab 100 mg;   Other: Placebo
    Sponsors:   University of North Carolina, Chapel Hill;   GlaxoSmithKline;   University of Utah;   Northwestern University;   Minnesota Gastroenterology, P.A.
    Recruiting
  • A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)
    NCT03941379
    Conditions:   Choroidal Melanoma;   Indeterminate Lesions of Eye
    Intervention:  
    Sponsor:   Aura Biosciences
    Recruiting
  • Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
    NCT03557385
    Condition:   Percutaneous Coronary Intervention
    Interventions:   Drug: Iopamidol;   Drug: adenosine;   Device: Navvus® Catheter;   Device: CVi® Contrast Delivery System
    Sponsors:   Duke University;   Acist Medical Systems
    Recruiting
  • Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
    NCT02396134
    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
    Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Wellclub Shoulder Therapy Outcome Validation
    NCT02954185
    Condition:   Shoulder Pain
    Interventions:   Device: WellClub;   Behavioral: Standard Therapy
    Sponsors:   University of Minnesota;   Fairview Sports Physical Therapy Program
    Recruiting
  • Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
    NCT03087708
    Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
    NCT03578081
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly
    NCT02121158
    Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
    Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
    NCT04114981
    Condition:   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Radiation: Single Fraction Stereotactic Radiosurgery;   Radiation: Fractionated Stereotactic Radiosurgery;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
    NCT04094688
    Condition:   Colorectal Adenocarcinoma
    Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
    NCT04071457
    Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Daratumumab/rHuPH20
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Janssen, LP;   Adaptive
    Recruiting
  • Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors
    NCT03996265
    Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Cancer Fatigue;   Cancer Survivor;   Complete Remission;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
    Interventions:   Drug: Bupropion Hydrochloride Controlled-release;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Gary Morrow;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Guiding Treatment for Patients With Brain Metastases
    NCT03994796
    Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
    Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
    Recruiting
  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
    NCT03984448
    Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
    NCT03944941
    Conditions:   Skin Squamous Cell Carcinoma;   Metastatic Skin Cancer
    Interventions:   Drug: Avelumab;   Drug: Cetuximab
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
    NCT03937635
    Condition:   Smoldering Plasma Cell Myeloma
    Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors
    NCT03887702
    Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm
    Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
    NCT03866382
    Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
    NCT03839940
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
    NCT03811015
    Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
    NCT03737994
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
    NCT03712605
    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
    NCT03707574
    Conditions:   Advanced Malignant Neoplasm;   Advanced Melanoma;   Advanced Renal Cell Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
    Intervention:   Procedure: Biospecimen Collection
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
    NCT03701308
    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Uproleselan
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
    NCT03694002
    Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
    NCT03654768
    Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
    NCT03609216
    Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
    Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
    NCT03475186
    Conditions:   Glioblastoma;   Radiotherapy; Complications;   Cognitive Decline;   Chemoradiation
    Intervention:   Drug: Ramipril
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
    NCT03375320
    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
    NCT03371719
    Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
    Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
    NCT03330405
    Condition:   Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
    Interventions:   Drug: Avelumab Phase 1b;   Drug: Talazoparib Phase 1b;   Drug: Avelumab Phase 2;   Drug: Talazoparib Phase 2
    Sponsor:   Pfizer
    Recruiting
  • Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
    NCT03304639
    Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
    Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
    NCT03224767
    Conditions:   BRAF V600E Mutation Present;   Papillary Craniopharyngioma
    Interventions:   Drug: Vemurafenib;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
    NCT03180294
    Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
    Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
    NCT03061305
    Conditions:   Cancer;   Adult Solid Tumor;   Lymphoma
    Intervention:  
    Sponsor:   Strata Oncology
    Recruiting
  • Stepped-Care Telehealth for Distress in Rural Cancer Survivors
    NCT03060096
    Conditions:   Anxiety;   Depressive Symptoms;   Sleep Disturbance;   Recurrent Disease;   Fatigue;   Quality of Life;   Cancer
    Interventions:   Other: Severe Anxiety/depression: High Intensity Stepped Care;   Other: Moderate Anxiety/depression: Low Intensity Stepped care;   Other: Enhanced Usual Care Control
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
    NCT02975934
    Condition:   Metastatic Castration Resistant Prostate Cancer
    Interventions:   Drug: Rucaparib;   Drug: Abiraterone acetate or Enzalutamide or Docetaxel
    Sponsors:   Clovis Oncology, Inc.;   Foundation Medicine
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
    NCT02822573
    Conditions:   Cognitive Dysfunction;   Memory Impairment
    Interventions:   Drug: Donepezil 5 mg;   Drug: Placebo
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
    NCT02775851
    Condition:   Desmoplastic Melanoma
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
    NCT02744092
    Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
    Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
    Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
    NCT02734537
    Conditions:   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant;   Lip and Oral Cavity Squamous Cell Carcinoma;   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC